Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBITDA (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed EBITDA for 12 consecutive years, with -$7.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 61.18% to -$7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$32.8 million through Dec 2025, down 35.68% year-over-year, with the annual reading at -$32.8 million for FY2025, 35.68% down from the prior year.
  • EBITDA hit -$7.9 million in Q4 2025 for vTv Therapeutics, up from -$10.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.6 million in Q3 2021 to a low of -$11.1 million in Q4 2021.
  • Historically, EBITDA has averaged -$6.3 million across 5 years, with a median of -$6.4 million in 2022.
  • Biggest YoY gain for EBITDA was 43.4% in 2021; the steepest drop was 707.05% in 2021.
  • Year by year, EBITDA stood at -$11.1 million in 2021, then soared by 42.9% to -$6.3 million in 2022, then rose by 25.79% to -$4.7 million in 2023, then fell by 3.93% to -$4.9 million in 2024, then tumbled by 61.18% to -$7.9 million in 2025.
  • Business Quant data shows EBITDA for VTVT at -$7.9 million in Q4 2025, -$10.7 million in Q3 2025, and -$7.7 million in Q2 2025.